VYNE Key Statistics, Chart & Performance
The current stock price of VYNE is 0.5661 USD. In the past month the price decreased by -2.41%. In the past year, price decreased by -75.91%.
VYNE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to VYNE. When comparing the yearly performance of all stocks, VYNE is a bad performer in the overall market: 76.37% of all stocks are doing better.
VYNE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VYNE. VYNE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VYNE Financial Highlights
Over the last trailing twelve months VYNE reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS increased by 9.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.12% | ||
| ROE | -104.86% | ||
| Debt/Equity | 0 |
VYNE Forecast & Estimates
10 analysts have analysed VYNE and the average price target is 3.32 USD. This implies a price increase of 485.59% is expected in the next year compared to the current price of 0.5661.
For the next year, analysts expect an EPS growth of 14.28% and a revenue growth -43.75% for VYNE
VYNE Ownership
About VYNE
Company Profile
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 13 full-time employees. The company went IPO on 2018-01-25. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Company Info
VYNE THERAPEUTICS INC
685 Route 202/206 N., Suite 301
Bridgewater NEW JERSEY 08807 US
CEO: David Domzalski
Employees: 13
Phone: 18007757936
VYNE THERAPEUTICS INC / VYNE FAQ
What does VYNE do?
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 13 full-time employees. The company went IPO on 2018-01-25. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Can you provide the latest stock price for VYNE THERAPEUTICS INC?
The current stock price of VYNE is 0.5661 USD. The price decreased by -0.07% in the last trading session.
What is the dividend status of VYNE THERAPEUTICS INC?
VYNE does not pay a dividend.
What is the ChartMill rating of VYNE THERAPEUTICS INC stock?
VYNE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the ownership structure of VYNE THERAPEUTICS INC (VYNE)?
You can find the ownership structure of VYNE THERAPEUTICS INC (VYNE) on the Ownership tab.
What is the Short Interest ratio of VYNE THERAPEUTICS INC (VYNE) stock?
The outstanding short interest for VYNE THERAPEUTICS INC (VYNE) is 5.32% of its float.